PDCD1 and neoplasm: With blood samples from 23 HNSCC patients who underwent anti-PD-1 immunotherapy upon tumour recurrence, we found that nonresponders to anti-PD-1 immunotherapy exhibited a higher baseline level of circulating sEV PD-L1 than responders (Fig. 1d).